Literature DB >> 10712427

Normal physiology and HIV pathophysiology of human T-cell dynamics.

D D Richman1.   

Abstract

Entities:  

Mesh:

Year:  2000        PMID: 10712427      PMCID: PMC292457          DOI: 10.1172/JCI9478

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  26 in total

1.  Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection.

Authors:  W Cavert; D W Notermans; K Staskus; S W Wietgrefe; M Zupancic; K Gebhard; K Henry; Z Q Zhang; R Mills; H McDade; C M Schuwirth; J Goudsmit; S A Danner; A T Haase
Journal:  Science       Date:  1997-05-09       Impact factor: 47.728

Review 2.  T cell turnover in HIV-1 disease.

Authors:  M K Hellerstein; J M McCune
Journal:  Immunity       Date:  1997-11       Impact factor: 31.745

3.  Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection.

Authors:  Z Q Zhang; D W Notermans; G Sedgewick; W Cavert; S Wietgrefe; M Zupancic; K Gebhard; K Henry; L Boies; Z Chen; M Jenkins; R Mills; H McDade; C Goodwin; C M Schuwirth; S A Danner; A T Haase
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

4.  Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.

Authors:  N G Pakker; D W Notermans; R J de Boer; M T Roos; F de Wolf; A Hill; J M Leonard; S A Danner; F Miedema; P T Schellekens
Journal:  Nat Med       Date:  1998-02       Impact factor: 53.440

5.  Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Authors:  J W Mellors; A Muñoz; J V Giorgi; J B Margolick; C J Tassoni; P Gupta; L A Kingsley; J A Todd; A J Saah; R Detels; J P Phair; C R Rinaldo
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

6.  T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover.

Authors:  K C Wolthers; G Bea; A Wisman; S A Otto; A M de Roda Husman; N Schaft; F de Wolf; J Goudsmit; R A Coutinho; A G van der Zee; L Meyaard; F Miedema
Journal:  Science       Date:  1996-11-29       Impact factor: 47.728

7.  Decay characteristics of HIV-1-infected compartments during combination therapy.

Authors:  A S Perelson; P Essunger; Y Cao; M Vesanen; A Hurley; K Saksela; M Markowitz; D D Ho
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

8.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

9.  Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.

Authors:  J K Wong; H F Günthard; D V Havlir; Z Q Zhang; A T Haase; C C Ignacio; S Kwok; E Emini; D D Richman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

10.  Telomere length, telomerase activity, and replicative potential in HIV infection: analysis of CD4+ and CD8+ T cells from HIV-discordant monozygotic twins.

Authors:  L D Palmer; N Weng; B L Levine; C H June; H C Lane; R J Hodes
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

View more
  3 in total

1.  Effectiveness of a 'hunter' virus in controlling human immunodeficiency virus type 1 infection.

Authors:  Gisela García-Ramos; Derik Castillo; Philip H Crowley
Journal:  J Gen Virol       Date:  2010-06-23       Impact factor: 3.891

2.  Viral and latent reservoir persistence in HIV-1-infected patients on therapy.

Authors:  Hwijin Kim; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2006-08-28       Impact factor: 4.475

Review 3.  Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis.

Authors:  Celestin Danwang; Jean Jacques Noubiap; Annie Robert; Jean Cyr Yombi
Journal:  AIDS Res Ther       Date:  2022-01-14       Impact factor: 2.250

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.